Accepted for Publication: August 9, 2022.
Published Online: October 12, 2022. doi:10.1001/jamadermatol.2022.4211
Corresponding Author: Yael A. Leshem, MD, MCR, Division of Dermatology, Rabin Medical Center, Beilinson Hopsital, 39 Zabotinsky St, Petah Tikva, Israel (yael.leshem@gmail.com).
Author Contributions: Dr Leshem had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Leshem, Chalmers, Apfelbacher, Katoh, Gerbens, Schmitt, Thomas, Williams.
Acquisition, analysis, or interpretation of data: Leshem, Chalmers, Apfelbacher, Katoh, Gerbens, Spuls, Howells, Williams, Simpson.
Drafting of the manuscript: Leshem, Katoh, Thomas.
Critical revision of the manuscript for important intellectual content: Chalmers, Apfelbacher, Katoh, Gerbens, Schmitt, Spuls, Howells, Williams, Simpson.
Statistical analysis: Leshem, Simpson.
Administrative, technical, or material support: Leshem, Chalmers, Katoh, Spuls.
Supervision: Apfelbacher, Katoh, Spuls, Thomas.
Conflict of Interest Disclosures: Dr Leshem reported grants from AbbVie; personal fees from AbbVie, Sanofi, Pfizer, Janssen, Genentech, Regeneron Pharmaceuticals, and Dexcel Pharma; and investigator services without personal compensation for Eli Lilly, Pfizer, and AbbVie outside the submitted work. Dr Apfelbacher reported grants and personal fees from Dr Wolff Group and Bionorica and personal fees from Sanofi and LEO Pharma outside the submitted work; and Dr Apfelbacher was involved in the group developing the RECAP instrument. Dr Katoh reported grants from Sun Pharma, Boehringer Ingelheim Japan, Mitsubishi Tanabe Pharma, and Eisai; grants and personal fees from Maruho, Eli Lilly Japan, Taiho Pharmaceutical, Torii Pharmaceutical, Kyowa Kirin, Sanofi, Janssen Pharma, AbbVie, LEO Pharma; and personal fees from Celgene Japan outside the submitted work. Dr Schmitt reported grants from Novartis, Pfizer, Sanofi, ALK, and Lilly (institutional grants for investigator-initiated trials) and personal fees from Sanofi, ALK, Lilly, and Novartis for advisory board participation outside the submitted work. Dr Spuls reported receiving departmental independent research grants for the systemic and phototherapy atopic eczema registry (TREAT NL) registry from pharmaceutical companies since December 2019, being involved in performing clinical trials with many pharmaceutical companies that manufacture drugs used for the treatment of (for example) psoriasis and atopic dermatitis, for which financial compensation was paid to the department/hospital, and is chief investigator of the TREAT NL registry for adults and children and one of the main investigators of the SECURE-AD registry; in addition, Dr Spuls was one of the investigators that developed the RECAP instrument for measuring long-term control in atopic dermatitis, all outside the submitted work. Dr Thomas reported involved in the development and validation of the RECAP questionnaire. Dr Howells reported personal fees from University of Oxford outside the submitted work and involvement in the development of the RECAP questionnaire (authors retain copyright). Dr Williams reported codevelopment of the POEM scale used for assessing AE symptoms. Dr Simpson reported personal fees from AbbVie, Amgen, Arena Pharmaceuticals, Aslan Pharma, Benevolent AI Bio Limited (“BAI”), BiomX Ltd, Bluefin Biomedicine Inc, Boehringer Ingelheim, Boston Consulting Group, Collective Acumen, Coronado, Dermira, Eli Lilly, Evidera, Excerpta Medica, Galderma, GlaxoSmithKline, Forte Bio RX, Incyte Dermatologics, Janssen, Kyowa Kirin, LEO Pharma, Merck, Novartis, Ortho Galderma, Pfizer, Physicians World LLC, Pierre Fabre Dermo-Cosmetique, Regeneron, Roivant, Sanofi Genzyme, SPARC India, Trevi Therapeutics, and Valeant, and grants from AbbVie, Amgen, Arcutis, Aslan, Castle Biosciences, Celgene, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Kymab, Kyowa Hakko Kirin, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and TARGET-DERM outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported by the Oregon Health & Science University (OHSU) Department of Dermatology.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: HOME VIII meeting attendees are listed in Supplement 2.
Additional Contributions: The authors would like to acknowledge the diligent administrative and technical support from Rebecca Field, BSB, and Joseph Kirkland, BFA, both of OHSU. They did not receive additional compensation beyond their OHSU salaries for their contributions. The OHSU Department of Dermatology funded the technical platform and technical support for conducting the virtual HOME meetings.
6.Busse
R , Klazinga
N , Panteli
D ,
et al, eds.
Improving Healthcare Quality in Europe: Characteristics, Effectiveness and Implementation of Different Strategies [Health Policy Series, No. 53]. European Observatory on Health Systems and Policies; 2019. Accessed February 16, 2022.
https://www.ncbi.nlm.nih.gov/books/NBK549276/ 7.OECD, World Health Organization.
Improving Healthcare Quality in Europe: Characteristics, Effectiveness and Implementation of Different Strategies. OECD Publishing; 2019. doi:
10.1787/b11a6e8f-en 15.Schmitt
J , Langan
S , Stamm
T , Williams
HC ; Harmonizing Outcome Measurements in Eczema (HOME) Delphi panel. Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process.
J Invest Dermatol. 2011;131(3):623-630. doi:
10.1038/jid.2010.303PubMedGoogle ScholarCrossref 16.Schmitt
J , Spuls
PI , Thomas
KS ,
et al; HOME initiative collaborators. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.
J Allergy Clin Immunol. 2014;134(4):800-807. doi:
10.1016/j.jaci.2014.07.043PubMedGoogle ScholarCrossref 17.Spuls
PI , Gerbens
LAA , Simpson
E ,
et al; HOME initiative collaborators. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.
Br J Dermatol. 2017;176(4):979-984. doi:
10.1111/bjd.15179PubMedGoogle ScholarCrossref 19.Vincent
R , Chalmers
JR , McWilliams
C ,
et al. Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments.
Br J Dermatol. 2020;183(3):566-568. doi:
10.1111/bjd.19030PubMedGoogle ScholarCrossref 20.Leshem
YA , Chalmers
JR , Apfelbacher
C ,
et al; Harmonising Outcome Measures for Eczema (HOME) initiative. Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative.
J Am Acad Dermatol. 2020;82(5):1181-1186. doi:
10.1016/j.jaad.2019.12.055PubMedGoogle ScholarCrossref 21.Ogrinc
G , Davies
L , Goodman
D , Batalden
P , Davidoff
F , Stevens
D . SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.
BMJ Qual Saf. 2016;25(12):986-992. doi:
10.1136/bmjqs-2015-004411PubMedGoogle ScholarCrossref 23.Howells
LM , Chalmers
JR , Cowdell
F , Ratib
S , Santer
M , Thomas
KS . ‘When it goes back to my normal I suppose’: a qualitative study using online focus groups to explore perceptions of ‘control’ among people with eczema and parents of children with eczema in the UK.
BMJ Open. 2017;7(11):e017731. doi:
10.1136/bmjopen-2017-017731PubMedGoogle ScholarCrossref 24.Howells
L , Thomas
KS , Sears
AV ,
et al; long-term control of eczema working group for the HOME initiative. Defining and measuring ‘eczema control’: an international qualitative study to explore the views of those living with and treating atopic eczema.
J Eur Acad Dermatol Venereol. 2019;33(6):1124-1132. doi:
10.1111/jdv.15475PubMedGoogle ScholarCrossref 26.Chalmers
JR , Thomas
KS , Apfelbacher
C ,
et al. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).
Br J Dermatol. 2018;178(5):e332-e341. doi:
10.1111/bjd.16543PubMedGoogle ScholarCrossref 27.Stuart
BL , Howells
L , Pattinson
RL ,
et al. Measurement properties of patient-reported outcome measures for eczema control: a systematic review.
J Eur Acad Dermatol Venereol. 2021;35(10):1987-1993. doi:
10.1111/jdv.17335PubMedGoogle ScholarCrossref 31.Gerbens
LA , Prinsen
CA , Chalmers
JR ,
et al; Harmonising Outcome Measures for Eczema (HOME) initiative. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review.
Allergy. 2017;72(1):146-163. doi:
10.1111/all.12959PubMedGoogle ScholarCrossref 33.Silverberg
JI , Chiesa Fuxench
ZC , Gelfand
JM ,
et al. Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults.
Ann Allergy Asthma Immunol. 2018;121(6):729-734.e4. doi:
10.1016/j.anai.2018.07.040PubMedGoogle ScholarCrossref 34.Yosipovitch
G , Reaney
M , Mastey
V ,
et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
Br J Dermatol. 2019;181(4):761-769. doi:
10.1111/bjd.17744PubMedGoogle ScholarCrossref 36.Silverberg
JI , Lai
JS , Patel
KR ,
et al. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.
Br J Dermatol. 2020;183(5):891-898. doi:
10.1111/bjd.18978PubMedGoogle ScholarCrossref 39.Howells
LM , Chalmers
JR , Gran
S ,
et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP).
Br J Dermatol. 2020;183(3):524-536. doi:
10.1111/bjd.18780PubMedGoogle ScholarCrossref 41.Thomas
KS , Apfelbacher
CA , Chalmers
JR ,
et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Br J Dermatol. 2021;185(1):139-146. doi:
10.1111/bjd.19751PubMedGoogle ScholarCrossref 45.Paller
AS , Lai
JS , Jackson
K ,
et al. Generation and validation of the Patient-Reported Outcome Measurement Information System Itch Questionnaire-Child (PIQ-C) to measure the impact of itch on life quality.
J Invest Dermatol. 2022;142(5):1309-1317.e1. doi:
10.1016/j.jid.2021.10.015PubMedGoogle ScholarCrossref